Lv3
340 积分 2022-05-13 加入
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
2天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2天前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
13天前
已完结
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Stapokibart in Healthy Volunteers and Adult Subjects with Atopic Dermatitis
1个月前
已完结
Synthetic lethality in cancer drug discovery: challenges and opportunities
1个月前
已完结
Synthetic lethal strategies for the development of cancer therapeutics
1个月前
已完结
Life science ecosystems in Asia: biomedical innovation trends over the past decade
8个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
1年前
已完结
皖公网安备34019202002308
